Business Context and Reporting Period
This Form 8-K reports on the Annual General Meeting (AGM) of Bicycle Therapeutics plc held on June 17, 2026. The filing details the voting results for nine ordinary resolutions submitted to security holders. The meeting included 49,696,908 ordinary shares, representing approximately 98.64% of issued and outstanding shares.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting. It does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing references the adoption of U.K. statutory annual accounts for the year ended December 31, 2025, but does not disclose the numerical values contained within those accounts.
Material Changes and Voting Results
All nine proposals presented at the AGM were duly passed. Key voting outcomes include:
- Director Re-elections: Felix Baker and Hervé Hoppenot were re-elected as directors.
- Auditor Ratification: Shareholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm and U.K. statutory auditors for the year ending December 31, 2026.
- Compensation: The advisory vote on executive compensation and the directors' remuneration report for 2025 were approved. The new directors' remuneration policy was also approved to take effect immediately.
- Financial Statements: The U.K. statutory annual accounts and reports for the year ended December 31, 2025, were received and adopted.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk disclosures beyond the standard procedural notes regarding voting procedures and proxy appointments. The document notes that detailed descriptions of proposals are contained in the definitive proxy statement on Schedule 14A filed on April 22, 2026.
Investor Verification Checklist
- Verify the specific financial figures for the year ended December 31, 2025, by reviewing the referenced U.K. statutory annual accounts and the Schedule 14A proxy statement.
- Confirm the terms of the new directors' remuneration policy approved at the AGM.
- Review the Schedule 14A filed on April 22, 2026, for detailed descriptions of the proposals and voting procedures.
- Note that the filing date is June 18, 2026, confirming the timeliness of the AGM reporting.